Boston Scientific just scored a clean bill of health from analysts, with Leerink Partners launching coverage and slapping on an “outperform” rating along with a target price of $118. Twenty-two ...

A multistate outbreak of Salmonella enteritidis in June 2025, linked to contaminated eggs from a California facility, led to 79 cases and a major recall. The incident underscores the critical role ...

When assessing Boston Scientific’s valuation against the S&P 500, the stock presents as notably expensive across key metrics. The company’s price-to-sales (P/S) ratio stands at 8.3 ...

Boston Scientific Corporation’s relative price strength rank of 70 means that its weighted four-quarter return ranks in the 70 th percentile of all U.S.-listed stocks. This score reflects the ...

BOSTON — An old school building in Boston’s Hyde Park neighborhood, once vacant and “creepy,” is now buzzing with life while teaching new lessons in community and inclusion. Exactly one ...

The firm initiated Boston Scientific and Medtronic with Outperform ratings, citing company-specific catalysts and improving fundamentals, and set price targets of $118 and $110, respectively. Abbott ...

Return on Equity (ROE): Boston Scientific's ROE excels beyond industry benchmarks, reaching 3.06%. This signifies robust financial management and efficient use of shareholder equity capital.

Review the current valuation for Boston Scientific Corp (BSX:XNYS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

CBS Sports brings you live coverage, scoring, expert picks and stats for the MLB matchup between Boston Red Sox and Seattle Mariners on June 16, 2025 ...

Boston Scientific appears to be flexing a premium price tag that’s a bit too buff for its own balance sheet. Analysts using a two-stage Discounted Cash Flow (DCF) model calculated an intrinsic value ...